Moderna COVID-19 mRNA-1273 Vaccine
Jump to navigation
Jump to search
A Moderna COVID-19 mRNA-1273 Vaccine is a Moderna COVID-19 vaccine (for SARS-CoV-2).
- AKA: mRNA-1273.
- Context:
- It can encode the prefusion-stabilized full-length spike protein of SARS-CoV-2, triggering the immune system to recognize and fight the virus.
- It can be administered as a two-dose series, with doses typically spaced 28 days apart to achieve optimal immunity.
- It can be updated periodically to target new variants of SARS-CoV-2, with the goal of maintaining efficacy as the virus evolves.
- It can be authorized for emergency use or fully approved by regulatory agencies such as the FDA, EMA, and WHO.
- It can generate an immune response with side effects such as injection site pain, fatigue, headache, and mild fever, which usually resolve in a few days.
- It can be widely distributed through national and global vaccination programs to reduce COVID-19 transmission and severity.
- ...
- Example(s):
- the original mRNA-1273 vaccine formulation, which was highly effective during the early stages of the COVID-19 pandemic.
- an updated Moderna mRNA-1273 vaccine, specifically designed to protect against more recent SARS-CoV-2 variants.
- ...
- Counter-Example(s):
- Pfizer-BioNTech COVID-19 Vaccine, which is another mRNA vaccine but developed by Pfizer and BioNTech.
- Janssen COVID-19 Vaccine, a COVID-19 vaccine that uses an adenovirus vector instead of mRNA.
- Inactivated Virus COVID-19 Vaccine, such as CoronaVac, which utilizes an inactivated virus rather than mRNA technology.
- See: Moderna COVID-19 Vaccine, mRNA Technology, Spike Protein, SARS-CoV-2, Emergency Use Authorization, COVID-19 Immunization Program
References
2021
- (Baden et al., 2021) ⇒ Lindsey R. Baden, Hana M. El Sahly, Brandon Essink, Karen Kotloff, Sharon Frey, Rick Novak, David Diemert et al. (2021). "Efficacy and Safety of the MRNA-1273 SARS-CoV-2 Vaccine.” New England Journal of Medicine 384, no. 5.
- QUOTE: “The mRNA-1273 vaccine demonstrated high efficacy in a